BTS: India's Ozempic Paradox

About this episode

The episode explores the complexities of drug availability and access in India following the generic release of Ozempic.

For years, a single drug sat behind a patent wall – expensive, scarce and out of reach for most of the world. And then, almost overnight, that wall collapsed. A patent expired. Dozens of Indian pharma companies moved in. Factories spun up. Regulators cleared approvals. And within days, Ozempic, one of the most talked-about drugs in the world, was suddenly available in India at a fraction of its American price. At ₹1,290 a month, finally, a miracle drug for the masses. But beneath the celebration, something didn’t add up. Because in a country with over 250 million people living with obesity, only about 200,000 are actually using it. This is not just a story about Ozempic. It’s a story about pricing, perception, culture, and the strange gap between availability and reality. From patent laws and pharma economics to celebrity denial cycles and black-market injections, from American shortages to India’s emerging demand – this episode unpacks what really happens when a “wonder drug” goes generic. Because abundance isn’t the same as access. And cheap isn’t the same as affordable. Today, we break down the business, culture, and unintended consequences behind India’s Ozempic moment, and…

People in this episode

Host: Akash Bhat

Topics covered

• pharmaceuticals
• healthcare access
• obesity
• drug pricing
• cultural perceptions
• generic drugs

Keywords

• Ozempic
• India
• drug pricing
• obesity
• healthcare
• generic drugs
• pharmaceutical economics

Mentioned in this episode

Products: Ozempic

Places: India, America